Respiratory Disease Genetic Testing Market Size is predicted to witness a 5.34% CAGR during the forecast period for 2023-2031.
Respiratory disease is a pathological condition that affects the respiratory system, primarily the lungs. Respiratory ailments encompass asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pneumonia, and lung cancer. Testing for respiratory diseases is the most basic and widely performed examination of the lungs. Pollution, smoking, and an ageing population are all contributing to a rise in the prevalence of these diseases. Genetic testing greatly affects respiratory disease diagnosis and treatment. By identifying at-risk patients early, genetic testing allows for timely intervention and individualized treatment. Genetic profiles assist clinicians identify the best medicines, reducing trial-and-error and improving patient outcomes. Genetic testing helps families screen for respiratory illness predispositions, enabling prevention.
Furthermore, the COVID-19 pandemic has had a major impact on the expansion of the market for testing for respiratory diseases. Improvements in patient outcomes have resulted from these innovations' facilitation of early diagnosis and individualized treatment. Rapid technological change has resulted in a shortage of appropriately trained professionals. Due largely to a shortage of qualified specialists, instrumentation and procedure execution have suffered. Investing in equipment and chemicals and ensuring quality control for a state-of-the-art laboratory for testing for respiratory diseases can add up quickly.
In addition, Demand for COVID-19 testing has increased because of the pandemic. However, this has come at the expense of focusing on other respiratory disorders. The total number of tests performed and the resources available for testing respiratory diseases other than COVID-19 may have been temporarily reduced due to this diversion.
Competitive Landscape
Some Major Key Players In The Respiratory Disease Genetic Testing Market:
- 23andMe, Inc.
- Centogene A.G.
- GeneDx, Inc.(Sema4)
- Invitae Corporation
- Color Genomics
- Myriad Genetics
- Medicover Genetics
- Blueprint Genetics
- Prevention Genetics
- Quest Diagnostics
- Genesis Genetics
- ARUP Laboratories
- EGL Genetic Diagnostics
- Laboratory Corporation of America Holdings (LabCorp)
- Others
Market Segmentation:
The respiratory disease genetic testing market is segmented based on offerings, disease type, technology, trait type, age group and end-user. By Offerings, market is divided into Products (Kits and Consumables), Services, and Others. By Disease Type segment, the market is segmented into COPD (Alpha-1-antitrypsin (AAT), Cystic Fibrosis (CF), Diffuse Lung Disease/Surfactant Dysfunction (RHD (Respiratory Distress Syndrome), PPHN (Persistent Pulmonary Hypertension of the Newborn)), Interstitial lung disease, Pulmonary Arterial Hypertension, Pulmonary Hypoplasia, Primary Ciliary Dyskinesia, Other Diseases (BPD)).
Whereas, By Technology, the market is divided into PCR, NGS (Whole Genome Sequencing, Whole Exome Sequencing), and Others (Targeted Sequencing, Karyotyping, and FISH)). As per the Trait Type, the market is categorized into Inherited Trait, and Acquired Trait. The Age Group segment includes Children, and Adult. At last, the End-User comprises Hospital Laboratories, Diagnostics Laboratories, Genetic Testing Laboratories, Research Laboratories, and Other End User
Based On The Offering, The Product Segment Is Accounted As A Major Contributor To The Respiratory Disease Genetic Testing Market.
The products category is expected to hold a major global market share. Kits and consumables are most significant factors for market growth. The availability and advancements of products in the applications are responsible to boost the Respiratory Disease Genetic Testing Market.
Disease Type Segment Is Expected To Witness Growth At A Rapid Rate.
The disease type segment comprises COPD and cystic Frosis which will drive the segment due to increasing prevelence. Also, rise in rapid diagnositcs services are responsible for the segment development.
In The Region, The North American Respiratory Disease Genetic Testing Market Holds A Significant Revenue Share.
The North American respiratory disease genetic testing market is expected to record the maximum market share in revenue in the near future. It can be attributed to the high healthcare expenditure and a developed infrastructure. Additionally, the high prevalence of respiratory disorders, such as asthma, COPD, and lung cancer, contributes to the demand for respiratory disease testing in North America. In addition, Asia Pacific is estimated to grow rapidly in the global respiratory disease genetic testing market because large populations, growing urbanization, higher levels of education and awareness of respiratory disorders, and better healthcare infrastructure are all driving forces behind this expansion. Air pollution, tobacco use, and altered diets have all contributed to an increase in respiratory illnesses in the area.
Recent Developments:
- In June 2023, Centogene and Lifera formed a partnership in Saudi Arabia to provide genetic testing. Centogene, a genetic data diagnostics company with operations in both Germany and the United States, contributed its extensive Biodatabank pertaining to rare diseases. Lifera, a biopharmaceutical corporation owned by the Public Investment Fund of Saudi Arabia, established a network for genetic testing services by utilizing its presence in the country.
- In July 2023, Quest Diagnostics introduced its inaugural consumer-initiated genetic test, accessible exclusively via questhealth.com, the organization's consumer health division. Genetic Insights was a novel service that assisted individuals in comprehending their prospective susceptibility to specific hereditary ailments. It offered comprehensive support and cutting-edge technology, such as personalized health reports and genetic counselling services.
Respiratory Disease Genetic Testing Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 5.34% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Offerings, By Disease Type, By Offerings, By Trait Type, By Age Group, By End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
23andMe, Inc., Centogene A.G., GeneDx, Inc.(Sema4), Invitae Corporation, Color Genomics, Myriad Genetics, Medicover Genetics, Blueprint Genetics, Prevention Genetics, Quest Diagnostics, Genesis Genetics, ARUP Laboratories, EGL Genetic Diagnostics, Laboratory Corporation of America Holdings (LabCorp), and Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
